Table 4.

Treatment outcome

End point	No. failures	4-year estimates	95% CI	At risk
All ipsilateral breast failure (IBF)	3	6%	(0–12%)	40
Within field, invasive	2	4%	(0–9%)	40
Within field, noninvasive	0	0%	—	40
Outside field	1	2%	(0–6%)	40
Peripheral (skin)	1	2%	(0–6%)	40
IBF without concurrent distant failure	2	4%	(0–9%)	40
Ipsilateral nodal failure (protocol-defined)	1	2%	(0–6%)	42
Contralateral breast failure	0	0%	—	42
Distant failure	4	8%	(0–15%)	40
Mastectomy-free survival	6	90%	(78–96%)	39
Disease-free survival (see Table 5 for details)	8	84%	(71–92%)	37
Overall survival	3	96%	(85–99%)	42